Pfizer presented data indicating berobenatide’s long-acting monthly GLP-1 regimen delivers efficacy in patients with both obesity and diabetes, reinforcing the drug’s positioning after its Metsera acquisition. The updates were part of conference communications that aimed to extend validation beyond obesity-only cohorts. The company framed the obesity-and-diabetes dataset as supportive of dose strategy and clinical performance across mixed metabolic populations. The additional evidence is intended to strengthen payer and prescriber confidence ahead of competitive comparisons with weekly GLP-1 and newer incretin combinations. As obesity treatment paradigms diversify, diabetes comorbidity response has become a key differentiator for label outcomes and real-world coverage decisions.